Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.

Keeney M, Halley JG, Rhoads DD, Ansari MQ, Kussick SJ, Karlon WJ, Mehta KU, Dorfman DM, Linden MA.

Arch Pathol Lab Med. 2015 Oct;139(10):1276-80. doi: 10.5858/arpa.2014-0543-CP.

PMID:
25695342
2.

Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, Landgren O.

Nat Rev Clin Oncol. 2015 May;12(5):286-95. doi: 10.1038/nrclinonc.2014.239. Review.

PMID:
25622976
3.

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B.

Cytometry B Clin Cytom. 2016 Jan;90(1):31-9. doi: 10.1002/cyto.b.21228.

4.

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.

Flanders A, Stetler-Stevenson M, Landgren O.

Blood. 2013 Aug 8;122(6):1088-9. doi: 10.1182/blood-2013-05-506170. No abstract available.

Supplemental Content

Loading ...
Support Center